This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nicolin, A. Articles by Goldin, A. Search for Related Content PubMed PubMed Citation Articles by Nicolin, A. Articles by Goldin, A.

Adoptive Immunotherapy in BALB/c x DBA/2 Cr F₁ Mice Bearing an Immunogenic Subline of L1210 Leukemia

Institute of Pharmacology, School of Medicine, University of Milan 20129, Milan, Italy [A. N., G. C.], and Drug Research and Development, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland 20014 [A. G.]

That treatment with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC) in vivo may have induced new antigen(s) on L1210/Ha leukemia cells is supported by the finding of spleen cells in sensitized mice that are specifically immune to the DIC-treated L1210/Ha leukemia (L1210/Ha/DIC).

An infusion of immune spleen cells "cured" immunosuppressed BALB/c x DBA/2 Cr F₁ mice bearing the L1210/Ha/DIC leukemia and did not exhibit any therapeutic activity in mice bearing 10⁶ cells of the parental L1210/Ha leukemia. Spleen cells that are immune to syngeneic or allogeneic tumor cells did not protect the mice challenged with 10⁶ L1210/Ha/DIC cells.

The therapeutic activity of immune spleen cells is increased as the number of cells is increased. The extent of activity was influenced by the size of the tumor inoculum, the time of lymphocyte transfusion following inoculation of viable leukemia, and the amount of sensitizing antigen. Adoptive immunotherapy using L1210/Ha cells with increased immunogenicity resulting from in vivo DIC treatment provides a potential approach for experimental cancer therapy.

¹ Supported in part by "Centro diFarmacologia delle infrastrutture," Consiglio Nazionale delle Ricerche, Rome, Italy.

Received 5/ 6/74. Accepted 7/30/74.